Dr Toshner is an active clinician, working predominantly in patients with pulmonary hypertension and chronic thromboembolic disease. He is the Director of the national pulmonary hypertension experimental medicine network, UniPHy, and his research group is focused on improving outcomes for patients with pulmonary hypertension using adaptive, decentralised and digital techniques in trial design coupled to investigator-driven networks to improve efficiency of drug validation in early phase trials. He was Chief-Investigator for the first UK pulmonary hypertension trial to recruit from all specialist centres within the UK and has been a Chief-Investigator, Co-Investigator, or Sub-Investigator in 22 phase 2-3 clinical trials, including four therapies and a vaccine that have achieved marketing authorisation. He is Joint Chief-Investigator for HEAL-COVID, the world’s first decentralised therapeutic platform trial for the post-hospital phase of Covid-19.